Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNMBiotechnology
-$0.39 today
- Market cap
- $326.66M
- Beta
- 0.89
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$1.57
Volume 0.20M
Average 0.26M
CTNM Interest Income
Income earned on cash, deposits, and investments held by the company.
Contineum Therapeutics, Inc. Class A Common StockNASDAQ: CTNM
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income growth accelerates
Q1 FY2026 interest income of $2.51M rose 11.3% year over year, ahead of the -10.7% change in trailing-twelve-month interest income. Sequentially, it rose 24.6% from the prior quarter. Over 3 fiscal years it compounded at +121.3% a year.
Context
- Interest income increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +11.3% holds above the trailing-twelve-month pace of -10.7%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 8.25M USD
- Year-over-year change
- -7.4%
- 4-year CAGR
- +221.7%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8.25M | -7.4% |
| FY2024 | 2024-12-31 | 8.91M | +93.3% |
| FY2023 | 2023-12-31 | 4.61M | +505.3% |
| FY2022 | 2022-12-31 | 761K | +888.3% |
| FY2021 | 2021-12-31 | 77K | — |
Interest Income vs competitors
How CTNM compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.7% is the 3rd highest of 7, against a peer median of -44.4%.
- Over three fiscal years its annual growth of +121.3% compares with a peer median of +167.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $14.93M USD | +11.7% | — | 74.6% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $8.5M USD | -10.7% | +121.3% | — |
| LTM Mar 2026 | $7.18M USD | +62.2% | +134.3% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $6.36M USD | — | +277.3% | — |
| LTM Mar 2026 | $6.34M USD | -30.5% | +286.9% | — | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $6.07M USD | -63.6% | +22.3% | — |
| LTM Mar 2026 | $2.32M USD | -61.0% | +45.2% | — | |
| LTM Mar 2026 | CHF 1.36M CHF | -58.3% | +200.1% | 36.6% | |
SPTXSeaport Therapeutics, Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding CTNM) | — | -44.4% | +167.2% | 55.6% | |
Competitors are the stored peer set for CTNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 50M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 258K | 0 |
| Gross Profit | 0 | 0 | 50M | (258K) | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 22.36M | 16.89M | 27.6M | 38.16M | 51.52M |
| Selling, General & Admin | 6.29M | 5.83M | 6.32M | 12.47M | 16.54M |
| Operating Expenses | 28.65M | 22.72M | 66.08M | 50.64M | 68.06M |
| Depreciation & Amortization | 325K | 329K | 195K | 258K | 323K |
| EBITDA | (28.34M) | (23.54M) | 23.57M | (42M) | (59.66M) |
| EBITDA Margin | — | — | 47.1% | — | — |
| Operating Income | (28.65M) | (22.72M) | (16.08M) | (50.89M) | (68.06M) |
| Operating Margin | — | — | -32.2% | — | — |
| Interest Income | 77K | 761K | 4.61M | 8.91M | 8.25M |
| Interest Expense | 332K | 388K | 208K | 0 | 0 |
| Other Income / Expenses | (354K) | (1.53M) | 39.25M | 8.64M | 8.08M |
| Income Before Tax | (29M) | (24.25M) | 23.17M | (42.26M) | (59.98M) |
| Pre-Tax Margin | — | — | 46.3% | — | — |
| Income Tax Expense | 0 | 0 | 450K | 0 | 0 |
| Net Income | (29M) | (24.25M) | 22.72M | (42.26M) | (59.98M) |
| Net Margin | — | — | 45.4% | — | — |
| EPS (Basic) | (1.15) | (0.97) | 0.13 | (1.63) | (2.17) |
| EPS (Diluted) | (1.15) | (0.97) | 0.13 | (1.63) | (2.17) |
| Weighted Avg Shares | 25.13M | 25.13M | 25.13M | 25.85M | 27.7M |
| Weighted Avg Shares (Diluted) | 25.13M | 25.13M | 25.13M | 25.85M | 27.7M |
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
Intrinsic Alpha fair value
Locked
Current Price
$9.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.